Methylnaltrexone as a Method to Improve Ticagrelor Uptake in Morphine Treated STEMI Patients

• Status: Completed
• Trial end date: 2017-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will examine the impact of the peripheral opioid antagonist methylnaltrexone on the onset of effect of ticagrelor in morphine treated patients with ST elevation myocardial infarction (STEMI). Half of the participants will receive methylnaltrexone, while the other half will receive placebo.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Karolinska University Hospital
• Treatments: Bromides; Methylnaltrexone; Morphine; Naltrexone; Ticagrelor

Criteria

Inclusion Criteria:

• Diagnosis of STEMI

• Administration of a 180 mg loading dose ticagrelor

• Analgesic treatment with intravenous morphine pre-PCI

Exclusion Criteria:

• Cardiac arrest

• Body weight > 114kg

• Vomiting after intake of ticagrelor loading dose

• Use of Naloxone before inclusion or during sampling period

• Inability to understand study outline and instructions

• Methylnaltrexone bromide contraindication

• Age <18 years; 8) Women in fertile age

• Administration of ticagrelor during the week before inclusion

• Treatment with Cangrexal

• Ongoing long-term opioid treatment.